title: Review of systemic therapies for locally advanced and metastatic rectal cancer.
abstract: Rectal cancer, along with colon cancer, is the second leading cause of cancer-related deaths in the U.S. Up to a quarter of patients have metastatic disease at diagnosis and 40% will develop metastatic disease. The past 10 years have been extremely exciting in the treatment of both locally advanced and metastatic rectal cancer (mRC). With the advent of neoadjuvant chemoradiation, increased numbers of patients with locally advanced rectal cancer (LARC) are surviving longer and some are seeing their tumors shrink to sizes that allow for resection. The advent of biologics and monoclonal antibodies has propelled the treatment of mRC further than many could have hoped. Combined with regimens such as FOLFOX or FOLFIRI, median survival rates have been increased to an average of 23 months. However, the combinations of chemotherapy regimens seem endless for rectal cancer. We will review the major chemotherapies available for locally advanced and mRC as well as regimens currently under investigation such as FOLFOXIRI. We will also review vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) inhibitors as single agents and in combination with traditional chemotherapy regimens.
authors.affiliation: Samuel Oschin Comprehensive Cancer Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA.
authors.forename: Patrick
authors.initials: P
authors.lastname: Yaffee
authors.affiliation: Samuel Oschin Comprehensive Cancer Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA.
authors.forename: Arsen
authors.initials: A
authors.lastname: Osipov
authors.affiliation: Samuel Oschin Comprehensive Cancer Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA.
authors.forename: Carlyn
authors.initials: C
authors.lastname: Tan
authors.affiliation: Samuel Oschin Comprehensive Cancer Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA.
authors.forename: Richard
authors.initials: R
authors.lastname: Tuli
authors.affiliation: Samuel Oschin Comprehensive Cancer Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA.
authors.forename: Andrew
authors.initials: A
authors.lastname: Hendifar
keywords: Systemic therapies; chemotherapies; locally advanced and metastatic rectal cancer (mRC)
references.citation: J Clin Oncol. 2012 Jun 1;30(16):1926-33
references.pmid: 22529255
references.citation: Oncology. 2010;79(1-2):27-38
references.pmid: 21051914
references.citation: J Clin Oncol. 2009 Nov 1;27(31):5124-30
references.pmid: 19770376
references.citation: Semin Oncol. 2002 Oct;29(5 Suppl 15):21-33
references.pmid: 12422305
references.citation: J Clin Oncol. 2011 May 1;29(13):1757-64
references.pmid: 21422411
references.citation: J Clin Oncol. 2007 Sep 20;25(27):4224-30
references.pmid: 17548839
references.citation: Lancet Oncol. 2011 Oct;12 (11):1032-44
references.pmid: 21903473
references.citation: N Engl J Med. 2001 Aug 30;345(9):638-46
references.pmid: 11547717
references.citation: J Clin Oncol. 2007 Aug 20;25(24):3644-8
references.pmid: 17704414
references.citation: J Clin Oncol. 2008 Apr 20;26(12):2013-9
references.pmid: 18421054
references.citation: J Natl Cancer Inst. 1988 Mar 2;80(1):21-9
references.pmid: 3276900
references.citation: N Engl J Med. 2004 Jun 3;350(23 ):2335-42
references.pmid: 15175435
references.citation: Acta Oncol. 1998;37(3):285-9
references.pmid: 9677101
references.citation: Ann Oncol. 2011 Jun;22(6):1404-12
references.pmid: 21115602
references.citation: Ann Oncol. 2009 Jun;20(6):1042-7
references.pmid: 19153116
references.citation: Ann Oncol. 2011 Jul;22(7):1535-46
references.pmid: 21228335
references.citation: J Pathol. 1997 Jan;181(1):39-45
references.pmid: 9072001
references.citation: J Clin Oncol. 2012 Dec 20;30(36):4558-65
references.pmid: 23109696
references.citation: J Clin Oncol. 2002 Jan 1;20(1):81-7
references.pmid: 11773157
references.citation: J Clin Oncol. 2011 May 20;29(15):2011-9
references.pmid: 21502544
references.citation: J Clin Oncol. 2008 Apr 1;26(10 ):1626-34
references.pmid: 18316791
references.citation: Lancet Oncol. 2013 Jan;14(1):29-37
references.pmid: 23168366
references.citation: Acta Oncol. 2010 Apr;49(3):287-97
references.pmid: 20156114
references.citation: JAMA. 2008 Nov 19;300(19):2277-85
references.pmid: 19017914
references.citation: J Natl Cancer Inst. 2010 May 5;102(9):596-604
references.pmid: 20351338
references.citation: Genes Chromosomes Cancer. 2011 May;50(5):307-12
references.pmid: 21305640
references.citation: Cancer. 2007 Aug 1;110(3):670-7
references.pmid: 17559146
references.citation: N Engl J Med. 2009 Feb 5;360(6):563-72
references.pmid: 19196673
references.citation: J Clin Oncol. 2005 Aug 20;23(24):5644-50
references.pmid: 16110023
references.citation: J Support Oncol. 2008 Nov-Dec;6(8):373-8
references.pmid: 19149322
references.citation: J Clin Oncol. 2008 Jul 20;26(21):3523-9
references.pmid: 18640933
references.citation: J Clin Oncol. 2008 Dec 20;26(36):5910-7
references.pmid: 19018087
references.citation: J Clin Oncol. 2001 Apr 15;19(8):2282-92
references.pmid: 11304782
references.citation: Oncologist. 2009 Sep;14(9):862-70
references.pmid: 19726453
references.citation: J Clin Oncol. 2007 May 1;25(13):1670-6
references.pmid: 17470860
references.citation: J Clin Oncol. 2007 Sep 20;25(27):4217-23
references.pmid: 17548840
references.citation: Adv Pharmacol. 1994;29B:73-92
references.pmid: 8996602
references.citation: J Clin Oncol. 2005 Jun 1;23 (16):3697-705
references.pmid: 15738537
references.citation: N Engl J Med. 1985 Jun 6;312(23):1465-72
references.pmid: 2859523
references.citation: J Clin Oncol. 2012 May 20;30(15):1755-62
references.pmid: 22473155
references.citation: J Clin Oncol. 2008 Feb 1;26(4):689-90
references.pmid: 18235136
references.citation: Eur J Clin Pharmacol. 2011 Jun;67(6):613-23
references.pmid: 21243343
references.citation: J Clin Oncol. 2006 Sep 10;24(26):4228-35
references.pmid: 16896007
references.citation: N Engl J Med. 2008 Oct 23;359(17):1757-65
references.pmid: 18946061
references.citation: J Clin Oncol. 2007 Oct 10;25(29):4557-61
references.pmid: 17876013
references.citation: N Engl J Med. 1991 Mar 14;324(11):709-15
references.pmid: 1997835
references.citation: Clin Cancer Res. 1995 Nov;1(11):1311-8
references.pmid: 9815926
references.citation: J Clin Oncol. 2004 Dec 1;22(23):4753-61
references.pmid: 15570076
references.citation: Ann Oncol. 2013 Apr;24(4):960-5
references.pmid: 23175623
references.citation: J Clin Oncol. 2004 Jan 15;22(2):229-37
references.pmid: 14657227
references.citation: N Engl J Med. 2007 Nov 15;357(20):2040-8
references.pmid: 18003960
references.citation: J Clin Oncol. 2002 Jan 1;20(1):7-8
references.pmid: 11773147
references.citation: Drugs. 2011 Jun 18;71(9):1153-77
references.pmid: 21711061
references.citation: J Clin Oncol. 2005 Aug 1;23 (22):4856-65
references.pmid: 15939923
references.citation: J Natl Cancer Inst. 2007 Aug 15;99(16):1232-9
references.pmid: 17686822
references.citation: Semin Oncol. 2002 Oct;29(5 Suppl 15):11-20
references.pmid: 12422304
references.citation: Am J Clin Oncol. 2007 Aug;30(4):350-7
references.pmid: 17762434
references.citation: Eur J Cancer. 2002 Sep;38(13):1677-84
references.pmid: 12175683
references.citation: Cancer. 2008 May 1;112(9):1932-40
references.pmid: 18300238
references.citation: Nat Rev Drug Discov. 2004 Jan;3(1):11-2
references.pmid: 14756144
references.citation: J Clin Oncol. 2004 Sep 15;22(18):3766-75
references.pmid: 15365073
references.citation: Ann Oncol. 2002 Apr;13(4):566-75
references.pmid: 12056707
references.citation: Cancer. 2009 Oct 15;115(20):4849-56
references.pmid: 19626652
references.citation: Clin Cancer Res. 2003 Aug 15;9(9):3246-53
references.pmid: 12960109
references.citation: J Clin Invest. 1995 Apr;95(4):1897-905
references.pmid: 7706497
references.citation: JAMA. 1990 Sep 19;264(11):1444-50
references.pmid: 2202842
references.citation: Clin Cancer Res. 2007 Jun 1;13(11):3269-75
references.pmid: 17510208
references.citation: Lancet Oncol. 2010 Aug;11(8):753-62
references.pmid: 20619739
references.citation: J Clin Oncol. 2009 Feb 10;27(5):672-80
references.pmid: 19114685
references.citation: Am J Clin Oncol. 1998 Jun;21(3):279-83
references.pmid: 9626798
references.citation: J Clin Oncol. 2008 Nov 20;26(33):5326-34
references.pmid: 18854571
references.citation: J Clin Oncol. 1997 Jan;15(1):251-60
references.pmid: 8996150
references.citation: Lancet. 2011 Jun 18;377(9783):2103-14
references.pmid: 21641636
references.citation: Int J Colorectal Dis. 2008 Feb;23(2):139-45
references.pmid: 17909820
references.citation: N Engl J Med. 2013 Sep 12;369(11):1023-34
references.pmid: 24024839
references.citation: N Engl J Med. 2004 Jul 22;351(4):337-45
references.pmid: 15269313
references.citation: N Engl J Med. 2000 Sep 28;343 (13):905-14
references.pmid: 11006366
references.citation: Oncologist. 2007 Apr;12(4):443-50
references.pmid: 17470687
references.citation: Clin Cancer Res. 2005 Feb 1;11(3):1226-36
references.pmid: 15709193
references.citation: Cancer. 2013 Jan 15;119(2):438-44
references.pmid: 22786764
references.citation: J Clin Oncol. 2005 Aug 1;23(22):4866-75
references.pmid: 15939922
references.citation: Cochrane Database Syst Rev. 2012 Mar 14;(3):CD004078
references.pmid: 22419291
references.citation: J Clin Oncol. 2010 Nov 1;28(31):4697-705
references.pmid: 20921465
references.citation: J Clin Oncol. 2011 Jul 10;29(20):2773-80
references.pmid: 21606427
references.citation: JAMA. 2011 Feb 2;305(5):487-94
references.pmid: 21285426
references.citation: Pharmacol Ther. 1990;47(1):1-19
references.pmid: 2195551
references.citation: Lancet Oncol. 2012 Jul;13(7):679-87
references.pmid: 22627104
references.citation: J Clin Oncol. 2004 Jan 1;22(1):23-30
references.pmid: 14665611
references.citation: J Clin Oncol. 2003 Jun 1;21(11):2059-69
references.pmid: 12775730
references.citation: J Clin Oncol. 2006 Jul 1;24(19):3061-8
references.pmid: 16809730
references.citation: Eur J Cancer. 2006 Dec;42(18):3161-8
references.pmid: 17098421
references.citation: Lancet. 2000 Mar 25;355(9209):1041-7
references.pmid: 10744089
references.citation: J Clin Oncol. 2004 Apr 1;22(7):1209-14
references.pmid: 15051767
references.citation: Br J Cancer. 2004 Oct 18;91(8):1442-6
references.pmid: 15467766
references.citation: J Clin Oncol. 2008 May 10;26(14 ):2311-9
references.pmid: 18390971
references.citation: J Clin Oncol. 2009 Apr 10;27(11):1822-8
references.pmid: 19273701
references.citation: Cancer. 2004 Nov 15;101(10 ):2170-6
references.pmid: 15470715
references.citation: CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29
references.pmid: 24399786
references.citation: Cancer Chemother Pharmacol. 2000;45(4):291-7
references.pmid: 10755317
references.citation: J Am Soc Nephrol. 2010 Aug;21(8):1381-9
references.pmid: 20538785
references.citation: J Clin Oncol. 1997 Jan;15(1):368-81
references.pmid: 8996164
references.citation: N Engl J Med. 2009 Apr 2;360(14):1408-17
references.pmid: 19339720
references.citation: Ann Oncol. 2008 Oct;19(10 ):1720-6
references.pmid: 18550577
references.citation: J Clin Oncol. 2004 Apr 15;22(8):1382-8
references.pmid: 15007088
references.citation: Lancet Oncol. 2012 Jun;13(6):579-88
references.pmid: 22503032
references.citation: J Clin Oncol. 2002 Nov 1;20(21):4303-12
references.pmid: 12409328
references.citation: J Clin Oncol. 2007 Oct 20;25(30):4779-86
references.pmid: 17947725
references.citation: J Clin Oncol. 2007 May 1;25(13):1658-64
references.pmid: 17470858
references.citation: Genet Med. 2009 Jan;11(1):21-34
references.pmid: 19125129
references.citation: J Clin Oncol. 2000 Aug;18(16):2938-47
references.pmid: 10944126
references.citation: Clin Colorectal Cancer. 2012 Dec;11(4):238-46
references.pmid: 22658457
references.citation: Oncology. 2009;76(1):36-41
references.pmid: 19033714
references.citation: J Clin Oncol. 1998 Aug;16(8):2739-44
references.pmid: 9704726
references.citation: Eur J Clin Pharmacol. 2010 Aug;66(8):813-21
references.pmid: 20401474